Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 39

Results For "Biotech"

905 News Found

Thermo Fisher receives AIFA’s GMP approval for manufacturing facility of RNA-based products in Italy
News | January 22, 2024

Thermo Fisher receives AIFA’s GMP approval for manufacturing facility of RNA-based products in Italy

GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients


Novo Holdings expands portfolio in cancer diagnostics
News | January 22, 2024

Novo Holdings expands portfolio in cancer diagnostics

Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer


NATCO invests US$ 2 million in Cellogen Therapeutics
News | January 18, 2024

NATCO invests US$ 2 million in Cellogen Therapeutics

Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy


Agilent announces new ProteoAnalyzer system
News | January 17, 2024

Agilent announces new ProteoAnalyzer system

Automated parallel capillary electrophoresis system simplifies protein analysis


Aarti Pharmalabs sets up R&D Centre in Navi Mumbai
News | January 11, 2024

Aarti Pharmalabs sets up R&D Centre in Navi Mumbai

The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects


Lupin launches Varenicline Tablets in US
News | January 11, 2024

Lupin launches Varenicline Tablets in US

Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US


BioAsia 2024 to focus on data and AI for life sciences
News | January 11, 2024

BioAsia 2024 to focus on data and AI for life sciences

The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others


Shanghai Argo announces multi-program RNAi licenses with Novartis
News | January 11, 2024

Shanghai Argo announces multi-program RNAi licenses with Novartis

Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.


Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US
News | January 10, 2024

Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US

Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb